The ELIVATE study (NCT04065841) is assessing if licogliflozin alone or in combination with tropifexor, an agonist of the bile acid receptor FXR, improves fibrosis and/or NAS score in patients with NASH and fibrosis stage 2 or 3. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.